Paricalcitol and endothelial function in chronic kidney disease trial

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Endocrinology

Background:

• Altered vitamin D metabolism is common in chronic kidney disease (CKD).
• Low levels of active 1,25-dihydroxy-vitamin D are a hallmark of CKD.
• No randomized controlled trials have tested active vitamin D's effect on vascular function in CKD patients.

Purpose of the Study:

• To evaluate the effect of paricalcitol, an active form of vitamin D, on vascular function in patients with stage 3-4 CKD.
• To assess paricalcitol's impact on endothelium-dependent and endothelium-independent vasodilation.
• To investigate the relationship between paricalcitol treatment and parathormone levels in CKD patients.

Main Methods:

• A double-blinded randomized controlled trial (PENNY study) involving 88 patients with stage 3-4 CKD and elevated parathormone.
• Patients received either paricalcitol (2 μg/d for 12 weeks) or a placebo.
• Vascular function was assessed by measuring endothelium-dependent and endothelium-independent vasodilation, with flow-mediated dilation as the primary endpoint.

Main Results:

• Paricalcitol significantly reduced parathormone levels compared to placebo.
• Flow-mediated dilation increased by 1.8% in the paricalcitol group versus the placebo group after 12 weeks (P=0.016).
• The improvement in flow-mediated dilation was temporary, disappearing 2 weeks after treatment cessation. No effect on blood pressure or endothelium-independent vasodilation was observed.

Conclusions:

• Paricalcitol improves endothelium-dependent vasodilation in patients with stage 3-4 CKD.
• These findings support the hypothesis that vitamin D may have beneficial cardiovascular effects in CKD patients.
• Further research is warranted to explore the long-term cardiovascular implications of active vitamin D therapy in CKD.